Alx oncology reports first quarter 2024 financial results and provides corporate update

South san francisco, calif., may 09, 2024 (globe newswire) -- alx oncology holdings inc., (“alx oncology” or the “company”) (nasdaq: alxo), an immuno-oncology company developing therapies that block the cd47 immune checkpoint pathway, today reported financial results for the first quarter ended march 31, 2024, and provided a corporate update.
ALXO Ratings Summary
ALXO Quant Ranking